505490512 05/23/2019

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5537316

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
AEOX LIMITED	08/30/2018

RECEIVING PARTY DATA

Name:	WHEY FORWARD HEALTH INDUSTRIES LTD.
Street Address:	UNIT B8 WEST POINT INDUSTRIAL ESTATE
Internal Address:	PENARTH ROAD
City:	CARDIFF
State/Country:	UNITED KINGDOM
Postal Code:	CF11 8JQ

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16085445

CORRESPONDENCE DATA

Fax Number: (203)703-0801

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 203-703-0800

Email: patent@whipgroup.com Correspondent Name: WALTER B. WELSH Address Line 1: 600 SUMMER STREET

Address Line 4: STAMFORD, CONNECTICUT 06901

ATTORNEY DOCKET NUMBER:	07143-P0001A	
NAME OF SUBMITTER:	WALTER B. WELSH	
SIGNATURE:	/Walter B. Welsh/	
DATE SIGNED:	05/23/2019	

Total Attachments: 6

source=17E2449#page1.tif source=17E2449#page2.tif source=17E2449#page3.tif source=17E2449#page4.tif source=17E2449#page5.tif

PATENT 505490512

REEL: 049264 FRAME: 0847

source=17E2449#page6.tif

PATENT REEL: 049264 FRAME: 0848

Dated 30th August 2018

Assignment

between

Asox Limited

and

Whey Forward Health Industries Ltd.

PATENT REEL: 049264 FRAME: 0849

THIS ASSIGNMENT is dated 30th August 2018

Parties

- (1) AEOX LIMITED incorporated and registered in England and Wales with company number 10314920 whose registered office is at Unit B8 West Point Industrial Estate, Penarth Road, Cardiff, CF11 8JQ (Assignor).
- (2) WHEY FORWARD HEALTH INDUSTRIES LTD. incorporated and registered in England and Wales with company number 07832790 whose registered office is at Unit B8 West Point Industrial Estate, Penarth Road, Cardiff, CF11 8JQ (Assignee).

Background

- (A) The Assignor owns the Patent Application (defined below);
- (B) The Assignor has agreed to assign to the Assignee the Assigned Rights and the Assignee has agreed to accept the transfer, on the terms set out in this Agreement.

Agreed terms

1. Interpretation

The following definitions and rules of interpretation apply in this Agreement.

1.1 Definitions:

Invention means the invention entitled BLENDING BLADE AND APPARATUS, being the subject matter of the Patent Application.

Assigned Rights means PCT/EP2017/056035, and any future patent applications linked by one or more priorities to PCT/EP2017/056035 and all matter contained in PCT/EP2017/056035 and any and all:

- (a) national and regional phase applications of PCT/EP2017/056035;
 and
- (b) divisions, continuations and continuations-in-part of all such applications;
- (c) patents that may be granted pursuant to any of the aforesaid applications for their full period, including any re-issues, reexaminations, renewals, extensions and Supplementary Protection Certificates; and
- (d) any utility models that may be filed based on PCT/EP2017/056035.

2. Assignment

In consideration of the sum of £1.00 GBP (receipt of which the Assignor expressly acknowledges), the Assignor hereby assigns to the Assignee absolutely, all its right, title and interest in and to the Assigned Rights, including:

- (a) the absolute entitlement to any registrations granted pursuant to any
 of the applications comprised in the Assigned Rights;
- (b) the right to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of any of the Assigned Rights whether occurring before, on, or after the date of this Agreement; and
- (c) The right to claim priority from any of the applications comprised in the Assigned Rights.

3. Further assurance

At its own expense the Assignor shall, and shall use all reasonable endeavours to procure that any necessary third party shall, promptly execute and deliver such documents and perform such acts as may reasonably be required for the purpose of giving full effect to this Agreement, including:

- (a) registration of the Assignee as applicant or (as applicable) proprietor of the Assigned Rights; and
- (b) assisting the Assignee in obtaining, defending and enforcing the Assigned Rights, and assisting with any other proceedings which may be brought by or against the Assignee against or by any third party relating to the Assigned Rights.

4. Severance

If any provision or part-provision of this Agreement is or becomes invalid, illegal or unenforceable, it shall be deemed modified to the minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deemed deleted. Any modification to or deletion of a provision or part-provision under this clause shall not affect the validity and enforceability of the rest of this Agreement.

PATENT REEL: 049264 FRAME: 0851

5. Counterparts

This Agreement may be executed in any number of counterparts, each of which when executed shall constitute a duplicate original, but all the counterparts shall together constitute the one Agreement.

6. Governing law and Jurisdiction

This Agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation shall be governed by and construed in accordance with the law of England and Wales. Each party irrevocably agrees that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this Agreement or its subject matter or formation.

Executed by AEOX LIMITED, acting by 1/24 F/2011/1/02 - 2010	rus <u>31/08/18</u>
an authorised signatory	Authorised Signatory Date
	Director
	Authorised Signatory Position

Witnessed by KATIE CULLEN

Witnessed by KATIE CULLEN

Date 31/08/18

Witnessed by MATTHEW BLOKELD

11000 ach

Date 31/68/18:

Executed by WHEY FORWARD HEALTH INDUSTRIES LTD acting by Jos FAUKAUN FOLAFO: an authorised signatory

31/8/18

Authorised Signatory

Date

CEO

Authorised Signatory Position

Wilnessed by JAMES DARLINGTON

81.80.18 mg pm 31.08.18

Witnessed by MEGAN STEALEY

moundy

Date 31:08:18

5